SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment
Open Access
- 8 September 2023
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (11) , 2339-2355
Abstract
The protein phosphatase SHP2/PTPN11 has been reported to be a key modulator of proliferative pathways in a wide range of malignancies. Intriguingly, SHP2 has also been described as a critical regulator of the tumor microenvironment. Based on this evidence SHP2 is considered a multifaceted target in cancer, spurring the notion that the development of direct inhibitors of SHP2 would provide the twofold benefit of tumor intrinsic and extrinsic inhibition. In this review, we will discuss the role of SHP2 in cancer and the tumor microenvironment, and the clinical strategies in which SHP2 inhibitors are leveraged as combination agents to improve therapeutic response. Significance: The SHP2 phosphatase functions as a pleiotropic factor, and its inhibition not only hinders tumor growth but also reshapes the tumor microenvironment. Although their single-agent activity may be limited, SHP2 inhibitors hold the potential of being key combination agents to enhance the depth and the durability of tumor response to therapy.Keywords
All Related Versions
Funding Information
- Foundation for the National Institutes of Health (R01 CA196703-01)
This publication has 122 references indexed in Scilit:
- Genetic disruption of the PI3K regulatory subunits, p85 , p55 , and p50 , normalizes mutant PTPN11-induced hypersensitivity to GM-CSFHaematologica, 2012
- Non–lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cellsJournal of Experimental Medicine, 2011
- Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular CarcinogenesisCancer Cell, 2011
- SHP-2 Expression Negatively Regulates NK Cell FunctionThe Journal of Immunology, 2009
- The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cellsExperimental Cell Research, 2009
- Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesisBlood, 2009
- Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformationProceedings of the National Academy of Sciences, 2009
- The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and MigrationCancer Research, 2007
- PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθFEBS Letters, 2004
- The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factorsOncogene, 2001